Oral Complementary Medicine Use among People with Inflammatory Arthritis: An Australian Rheumatology Association Database Analysis
Open Access
- 5 June 2020
- journal article
- research article
- Published by Wiley in International Journal of Rheumatology
- Vol. 2020, 1-9
Abstract
Objectives. To describe oral complementary medicine (CM) use in people with inflammatory arthritis, associations with use, and changes in use over time. Methods. Demographic, clinical, and patient-reported outcome data from 5,630 participants with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA), and juvenile idiopathic arthritis (JIA) were extracted from the Australian Rheumatology Association Database (ARAD), a national observational database. CM use at entry into ARAD was ascertained for participants recruited between 2002 and 2018. CM was categorised according to the NIH/Cochrane schema (fatty acids, herbs, or supplements). Logistic regression was used to assess associations between demographic characteristics and CM use. Change in CM use between 2006 and 2016 was investigated using a nonparametric test for trend of rate by year. Results. 2,156 (38.3%) ARAD participants were taking CM at enrolment (RA: 1,502/3,960 (37.9%), AS: 281/736 (38.2%), PsA: 334/749 (44.6%), and JIA: 39/185 (21.1%)). CM use was more prevalent in women (OR 1.3; 95% CI: 1.13-1.50), those with tertiary education (OR 1.32; 95% CI: 1.13-1.55), private health insurance (OR 1.26; (95% CI: 1.10-1.44), drinking alcohol sometimes (OR 1.22; 95% CI: 1.05-1.43), poorer function (HAQ) (OR 1.13; 95% CI: 1.02-1.24), use of NSAID (OR 1.32; 95% CI 1.17-1.50), weak (OR 1.21; 95% CI 1.05-1.41) but not strong opioids, and less prevalent in current smokers (OR 0.76; 95%: CI 0.63-0.91). CM use was not associated with pain, disease activity, or quality of life. The most common CMs were fish oils ( users) followed by glucosamine (). Both declined in use over time between 2006 and 2016 (27.5% to 21.4%, trend and 15.5% to 6.4%, trend ), respectively. Conclusion. Oral CM use is common among Australians with inflammatory arthritis. Its use is greater among women and those with tertiary education. Fish oil and glucosamine, the most common CMs, both declined in use over time.
Keywords
Funding Information
- Australian Rheumatology Association (384330)
- Royal North Shore Hospital (384330)
- Monash University (384330)
- Cabrini Health (384330)
- National Health and Medical Research Council (384330)
- Pfizer Australia (384330)
This publication has 30 references indexed in Scilit:
- Use of complementary medicine products: a nationally representative cross-sectional survey of 2019 Australian adultsBMJ Open, 2019
- Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysisCochrane Database of Systematic Reviews, 2017
- Marine Oil Supplements for Arthritis Pain: A Systematic Review and Meta-Analysis of Randomized TrialsNutrients, 2017
- Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort studyBMC Musculoskeletal Disorders, 2015
- Complementary and Alternative Medicine Use Among Youth With Juvenile Arthritis: Are Youth Using CAM, but Not Talking About It?Journal of Adolescent Health, 2012
- Complementary and alternative medicines in ankylosing spondylitis: a cross-sectional studyClinical Rheumatology, 2008
- The continuing use of complementary and alternative medicine in South Australia: costs and beliefs in 2004Medical Journal of Australia, 2006
- Use of Complementary Therapies Among Primary Care Clinic Patients With Arthritis2004
- Non‐prescription complementary treatments used by rheumatoid arthritis patients attending a community‐based rheumatology practiceInternal Medicine Journal, 2002
- The Assessment of Quality of Life (AQoL) instrument: a psychometric measure of Health-Related Quality of LifeQuality of Life Research, 1999